| 1 |
2023 |
Jesse Lopes da Silva, Giselle de Souza Carvalho, Lucas Zanetti de Albuquerque, Fabiana Resende Rodrigues, Priscila Valverde Fernandes, Daniel Kischinhevsky, Andreia Cristina de Melo. Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications, Breast Cancer: Targets and Therapy. 2023; Volume 15: 337.
https://doi.org/10.2147/BCTT.S408743 |
| 2 |
2024 |
Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi. Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs), Cancer Treatment Reviews. 2024; 123: 102672102672.
https://doi.org/10.1016/j.ctrv.2023.102672 |
| 3 |
2024 |
Sanjana Sawant, Gaurav Gopal Naik, Alakh N. Sahu, Vijay A. Jagtap. Understanding the chemistry & pharmacology of antibody–drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives, Medical Oncology. 2024; 41: 301.
https://doi.org/10.1007/s12032-024-02542-y |
| 4 |
2023 |
Weiru Chi, Bingqiu Xiu, Min Xiong, Xuliren Wang, Pei Li, Qi Zhang, Jianjing Hou, Yuting Sang, Xujie Zhou, Ming Chen, Shuyue Zheng, Liyi Zhang, Jingyan Xue, Yayun Chi, Jiong Wu. MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer, International Journal of Molecular Sciences. 2023; 25: 221.
https://doi.org/10.3390/ijms25010221 |
| 5 |
2024 |
Ornella Garrone, Caterina A. M. La Porta. Artificial Intelligence for Precision Oncology of Triple-Negative Breast Cancer: Learning from Melanoma, Cancers. 2024; 16: 692.
https://doi.org/10.3390/cancers16040692 |
| 6 |
2024 |
Komal Jhaveri, Frederik Marmé. Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, Cancer Treatment Reviews. 2024; 123: 102670102670.
https://doi.org/10.1016/j.ctrv.2023.102670 |
| 7 |
2023 |
Md Abdus Subhan, Vladimir P. Torchilin. Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate, Pharmaceutics. 2023; 15: 1242.
https://doi.org/10.3390/pharmaceutics15041242 |
| 8 |
2023 |
Carmelo Laface, Francesco Giuliani, Assunta Melaccio, Maria Nicla Pappagallo, Anna Natalizia Santoro, Martina Perrone, Pierluigi De Santis, Chiara Guarini, Daniela Carrozzo, Palma Fedele. The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions, Journal of Clinical Medicine. 2023; 12: 6012.
https://doi.org/10.3390/jcm12186012 |
| 9 |
2024 |
Chrysanthi Koukoutzeli, Dario Trapani, Liliana Ascione, Elias Kotteas, Antonio Marra, Carmen Criscitiello, Giuseppe Curigliano. Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer, Clinical Medicine Insights: Oncology. 2024; 18: 11795549241260418.
https://doi.org/10.1177/11795549241260418 |
| 10 |
2023 |
Duygu Akca, Adrian Simon, Reinhard Buettner, Christiane Bruns, Wolfgang Schroeder, Thomas Zander, Florian Gebauer, Alexander Quaas. Syndecan‑1 expression is an independent favourable prognostic marker in oesophageal adenocarcinoma and represents a potential therapeutic target, Oncology Letters. 2023; 26: 356.
https://doi.org/10.3892/ol.2023.13942 |
| 11 |
2023 |
Marta Tapia, Cristina Hernando, María Teresa Martínez, Octavio Burgués, Cristina Tebar-Sánchez, Ana Lameirinhas, Anna Ágreda-Roca, Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lluch, Begoña Bermejo, Pilar Eroles. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies, Cancers. 2023; 15: 4522.
https://doi.org/10.3390/cancers15184522 |
| 12 |
2023 |
Xuan Huang, Mengxuan Zhu, Ruoxue Chen, Junjie Ni, Wenrui Zhao, Song Li, Xiaoling Lu, Heng Jiao, Xin Cao. Innovative drugs promote precision cancer therapy, Clinical Cancer Bulletin. 2023; 2: 1.
https://doi.org/10.1007/s44272-023-00002-8 |
| 13 |
2023 |
Joshua Hurwitz, Lucy Roxana Haggstrom, Elgene Lim. Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy, Pharmaceutics. 2023; 15: 2017.
https://doi.org/10.3390/pharmaceutics15082017 |
| 14 |
2025 |
Shiqiao Wang, Heng Pan, Zhiru Chen, Hui Zhou, Jiayi Chen, Guosheng Zou, Jiayu Huang, Qinghua Mei. Hematological toxicities in antibody–drug conjugates related with breast cancer: a pharmacovigilance study using FDA adverse event reporting system database, Expert Opinion on Drug Safety. 2025; 1.
https://doi.org/10.1080/14740338.2025.2449991 |
| 15 |
2022 |
Ciaran Devoy, Yensi Flores Bueso, Mark Tangney. Understanding and harnessing triple-negative breast cancer-related microbiota in oncology, Frontiers in Oncology. 2022; 12: 1020121.
https://doi.org/10.3389/fonc.2022.1020121 |
| 16 |
2024 |
Baohong Jiang, Sixuan Wu, Lijun Zeng, Yuanbin Tang, Lunqi Luo, Lianjie Ouyang, Wenjie Feng, Yeru Tan, Yuehua Li. Impact of NDUFAF6 on breast cancer prognosis: linking mitochondrial regulation to immune response and PD-L1 expression, Cancer Cell International. 2024; 24: 99.
https://doi.org/10.1186/s12935-024-03244-1 |
| 17 |
2022 |
Yueyang Liu, Weiwei Gong, Sarah Preis, Julia Dorn, Marion Kiechle, Ute Reuning, Viktor Magdolen, Tobias F. Dreyer. A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression, Life. 2022; 12: 1517.
https://doi.org/10.3390/life12101517 |
| 18 |
2022 |
Desh Deepak Singh, Hae-Jeung Lee, Dharmendra Kumar Yadav. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer, Frontiers in Pharmacology. 2022; 13: 1089066.
https://doi.org/10.3389/fphar.2022.1089066 |
| 19 |
2024 |
Yiran Tao, Ying Lu, Ting Xue, Qinhuai Lai, Hengrui Song, Xiaofeng Chen, Cuiyu Guo, Jinliang Yang, Yuxi Wang. Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer, Journal of Drug Targeting. 2024; 32: 1295.
https://doi.org/10.1080/1061186X.2024.2386621 |
